I’m sure you are correct in that there are things moving on several fronts and a clear path cannot be openly discussed at this point not only because of NDAs but also because of many unknowns or things in process still. I in no way was meaning to be negative as I do have confidence that they are doing what is best for shareholders and the future of leronlimab.

I find it odd that Trding mentioned last week that financing isn’t what makes OTC stock breakout, yet none of our science progress has much current impact on the share price. Sorry if I misstated something Trding, but i recalled it was something along those lines. I do think the science catalysts due 2H2019 will break things out permanently, but would be nice to get a bump with some non-dilutive financing before then.